1. BMPER Improves Vascular Remodeling and the Contractile Vascular SMC Phenotype.
- Author
-
Pankratz F, Maksudova A, Goesele R, Meier L, Proelss K, Marenne K, Thut AK, Sengle G, Correns A, Begelspacher J, Alkis D, Siegel PM, Smolka C, Grundmann S, Moser M, Zhou Q, and Esser JS
- Subjects
- Animals, Mice, Bone Morphogenetic Proteins metabolism, Cell Movement, Cell Proliferation, Cells, Cultured, Disease Models, Animal, Mice, Inbred C57BL, Muscle, Smooth, Vascular metabolism, Myocytes, Smooth Muscle metabolism, Phenotype, Neointima metabolism, Vascular Remodeling, Carrier Proteins metabolism
- Abstract
Dedifferentiated vascular smooth muscle cells (vSMCs) play an essential role in neointima formation, and we now aim to investigate the role of the bone morphogenetic protein (BMP) modulator BMPER (BMP endothelial cell precursor-derived regulator) in neointima formation. To assess BMPER expression in arterial restenosis, we used a mouse carotid ligation model with perivascular cuff placement. Overall BMPER expression after vessel injury was increased; however, expression in the tunica media was decreased compared to untreated control. Consistently, BMPER expression was decreased in proliferative, dedifferentiated vSMC in vitro. C57BL/6_Bmper+/- mice displayed increased neointima formation 21 days after carotid ligation and enhanced expression of Col3A1, MMP2, and MMP9. Silencing of BMPER increased the proliferation and migration capacity of primary vSMCs, as well as reduced contractibility and expression of contractile markers, whereas stimulation with recombinant BMPER protein had the opposite effect. Mechanistically, we showed that BMPER binds insulin-like growth factor-binding protein 4 (IGFBP4), resulting in the modulation of IGF signaling. Furthermore, perivascular application of recombinant BMPER protein prevented neointima formation and ECM deposition in C57BL/6N mice after carotid ligation. Our data demonstrate that BMPER stimulation causes a contractile vSMC phenotype and suggest that BMPER has the potential for a future therapeutic agent in occlusive cardiovascular diseases.
- Published
- 2023
- Full Text
- View/download PDF